• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

Efficacy and Safety of High-intensity Statins in Patients with Acute Myocardial Infarction: An Asian Perspective
ConclusionsAMI patients in Taiwan with HIS had similar clinical outcomes to those with non-HIS. Using HIS for effective reduction of low-density lipoprotein cholesterol is safe in Taiwan.
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research

The Disconnect Between Novel Oral Anticoagulant Eligibility and Provincial Drug Coverage: An Albertan Anticoagulation Clinic Audit
Publication date: August 2015 Source:Canadian Journal of Cardiology, Volume 31, Issue 8 Author(s): Sandeep K. Dhillon, M. Sean McMurtry, Tammy J. Bungard Canadian practice guidelines for nonvalvular atrial fibrillation (NVAF) recommend that most patients receive a novel oral anticoagulant (NOAC) in preference to warfarin to prevent stroke, but not all patients have insurance that covers NOACs. The gap between optimal therapy and drug coverage is unknown. We retrospectively assessed eligibility for NOACs in patients with NVAF at our single-centre anticoagulation clinic and ascertained whether provincial drug coverage w...
Source: Canadian Journal of Cardiology - July 26, 2015 Category: Cardiology Source Type: research

The Disconnect between Novel Oral Anticoagulant Eligibility & Provincial Drug Coverage: An Albertan Anticoagulation Clinic Audit
Publication date: Available online 25 February 2015 Source:Canadian Journal of Cardiology Author(s): Sandeep K. Dhillon , M Sean McMurtry , Tammy J. Bungard Canadian practice guidelines for non-valvular atrial fibrillation (NVAF) recommend most patients receive a novel oral anticoagulant (NOAC) in preference to warfarin to prevent stroke, but not all patients have insurance that covers NOACs. The gap between optimal therapy and drug coverage is unknown. We retrospectively assessed eligibility for NOACs in those with NVAF at our single-centre Anticoagulation Clinic and ascertained whether provincial drug coverage would be...
Source: Canadian Journal of Cardiology - February 25, 2015 Category: Cardiology Source Type: research